Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Product Highlight - viekira pak

30 Oct 2015
VIEKIRA PAK– ombitasvir, paritaprevir, ritonavir 12.5/7.5/50 mg tab copackaged with dasabuvir 250 mg film-coated tab,  an innovative treatment for genotype 1 chronic hepatitis C.
• All-oral, interferon-free prescription medicine that attacks the hepatitis C virus in 3 ways to help stop it from multiplying.1
97% overall virologic cure (SVR12) in a 12-weeks treatment (with or without RBV) on patients who infected with HCV GT1.1,2
Low rates of relapse and on-treatment virologic failure.1,3-5
Robust clinical development program of 6 pivotal Phase 3 trials (SAPPHIRE-I, SAPPHIRE-II, PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II) which ensures optimal treatment regimen for GT1 patients.1
 
References:
1. VIEKIRA PAK [package insert]. 2014-12 viekira pak tablet HK/Macao specific leaflet text (Based on US PI)
2
. European Association for the Study of the Liver. Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology. 2014; vol. 60: 392–420.
3. Hepatitis C Trust 2014. http://www.hepctrust.org.uk/News_Resources/Glossary/Glossary+of+terms.html. Accessed December, 2014.
4
. Quest Diagnostics: Hepatitis C Viral RNA, Qualitative TMA. http://www.questdiagnostics.com/testcenter/testguide.action?dc=TH_HCV_RNA_QualTMA. Accessed December, 2014.
5. American Association for the Study of Liver Diseases. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011. 

Further information is available in MIMS section 8p and New-In-This-Issue.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.